Literature DB >> 20056188

Engineering filamentous phage carriers to improve focusing of antibody responses against peptides.

Nienke E van Houten1, Kevin A Henry1, George P Smith2, Jamie K Scott3.   

Abstract

The filamentous bacteriophage are highly immunogenic particles that can be used as carrier proteins for peptides and presumably other haptens and antigens. Our previous work demonstrated that the antibody response was better focused against a synthetic peptide if it was conjugated to phage as compared to the classical carrier, ovalbumin. We speculated that this was due, in part, to the relatively low surface complexity of the phage. Here, we further investigate the phage as an immunogenic carrier, and the effect reducing its surface complexity has on the antibody response against peptides that are either displayed as recombinant fusions to the phage coat or are chemically conjugated to it. Immunodominant regions of the minor coat protein, pIII, were removed from the phage surface by excising its N1 and N2 domains (Delta3 phage variant), whereas immunodominant epitopes of the major coat protein, pVIII, were altered by reducing the charge of its surface-exposed N-terminal residues (Delta8 phage variant). Immunization of mice revealed that the Delta3 variant was less immunogenic than wild-type (WT) phage, whereas the Delta8 variant was more immunogenic. The immunogenicity of two different peptides was tested in the context of the WT and Delta3 phage in two different forms: (i) as recombinant peptides fused to pVIII, and (ii) as synthetic peptides conjugated to the phage surface. One peptide (MD10) in its recombinant form produced a stronger anti-peptide antibody response fused to the WT carrier compared to the Delta3 phage carrier, and did not elicit a detectable anti-peptide response in its synthetic form conjugated to either phage carrier. This trend was reversed for a different peptide (4E10(L)), which did not produce a detectable anti-peptide antibody response as a recombinant fusion; yet, as a chemical conjugate to Delta3 phage, but not WT phage, it elicited a highly focused anti-peptide antibody response that exceeded the anti-carrier response by approximately 65-fold. The results suggest that focusing of the antibody response against synthetic peptides can be improved by decreasing the antigenic complexity of the phage surface. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20056188      PMCID: PMC2830289          DOI: 10.1016/j.vaccine.2009.12.059

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  55 in total

1.  Immunisation with phage displaying peptides representing single epitopes of the glycoprotein G can give rise to partial protective immunity to HSV-2.

Authors:  A M Grabowska; R Jennings; P Laing; M Darsley; C L Jameson; L Swift; W L Irving
Journal:  Virology       Date:  2000-03-30       Impact factor: 3.616

Review 2.  Duration, combination and timing: the signal integration model of dendritic cell activation.

Authors:  Annalisa Macagno; Giorgio Napolitani; Antonio Lanzavecchia; Federica Sallusto
Journal:  Trends Immunol       Date:  2007-04-02       Impact factor: 16.687

3.  Parameters underlying distinct T cell-dependent polysaccharide-specific IgG responses to an intact gram-positive bacterium versus a soluble conjugate vaccine.

Authors:  Jesus Colino; Gouri Chattopadhyay; Goutam Sen; Quanyi Chen; Andrew Lees; David H Canaday; Anatoly Rubtsov; Raul Torres; Clifford M Snapper
Journal:  J Immunol       Date:  2009-07-01       Impact factor: 5.422

4.  Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.

Authors:  S M Cleveland; E Buratti; T D Jones; P North; F Baralle; L McLain; T McInerney; Z Durrani; N J Dimmock
Journal:  Virology       Date:  2000-01-05       Impact factor: 3.616

5.  Recombinant expression and neutralizing activity of an MHC class II binding epitope of toxic shock syndrome toxin-1.

Authors:  E Rubinchik; A W Chow
Journal:  Vaccine       Date:  2000-04-28       Impact factor: 3.641

6.  B cells extract and present immobilized antigen: implications for affinity discrimination.

Authors:  F D Batista; M S Neuberger
Journal:  EMBO J       Date:  2000-02-15       Impact factor: 11.598

7.  Murine monoclonal antibody 26 raised against tetanus toxoid cross-reacts with beta2-glycoprotein I: its characteristics and role in molecular mimicry.

Authors:  Aleksandra Inic-Kanada; Marijana Stojanovic; Irena Zivkovic; Dusko Kosec; Mileva Micic; Vladimir Petrusic; Snezana Zivancevic-Simonovic; Ljiljana Dimitrijevic
Journal:  Am J Reprod Immunol       Date:  2009-01       Impact factor: 3.886

8.  Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities.

Authors:  Alessandro Sette; Magdalini Moutaftsi; Juan Moyron-Quiroz; Megan M McCausland; D Huw Davies; Robert J Johnston; Bjoern Peters; Mohammed Rafii-El-Idrissi Benhnia; Julia Hoffmann; Hua-Poo Su; Kavita Singh; David N Garboczi; Steven Head; Howard Grey; Philip L Felgner; Shane Crotty
Journal:  Immunity       Date:  2008-06       Impact factor: 31.745

9.  Immunological evidence for functional rather than structural mimicry by a Shigella flexneri Y polysaccharide-mimetic peptide.

Authors:  Silvia Borrelli; Rehana B Hossany; B Mario Pinto
Journal:  Clin Vaccine Immunol       Date:  2008-05-07

10.  A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120.

Authors:  Alfredo Menendez; Daniel A Calarese; Robyn L Stanfield; Keith C Chow; Chris N Scanlan; Renate Kunert; Herman Katinger; Dennis R Burton; Ian A Wilson; Jamie K Scott
Journal:  FASEB J       Date:  2008-01-15       Impact factor: 5.191

View more
  20 in total

Review 1.  Developments in high-yield system expressed vaccines and immunotherapy.

Authors:  Marissa Geels; Kaiming Ye
Journal:  Recent Pat Biotechnol       Date:  2010-11

2.  Developing strategies to enhance and focus humoral immune responses using filamentous phage as a model antigen.

Authors:  Kevin A Henry; Armstrong Murira; Nienke E van Houten; Jamie K Scott
Journal:  Bioeng Bugs       Date:  2011-09-01

Review 3.  Overview of computational vaccinology: vaccine development through information technology.

Authors:  Nishita Vaishnav; Aparna Gupta; Sneha Paul; Georrge J John
Journal:  J Appl Genet       Date:  2014-12-23       Impact factor: 3.240

4.  Reactivity profiles of broadly neutralizing anti-HIV-1 antibodies are distinct from those of pathogenic autoantibodies.

Authors:  Harvir Singh; Kevin A Henry; Sampson S T Wu; Andrzej Chruscinski; Paul J Utz; Jamie K Scott
Journal:  AIDS       Date:  2011-06-19       Impact factor: 4.177

5.  Structural requirements for the activity of the MirB ferrisiderophore transporter of Aspergillus fumigatus.

Authors:  Isabelle Raymond-Bouchard; Cassandra S Carroll; Jason R Nesbitt; Kevin A Henry; Linda J Pinto; Mina Moinzadeh; Jamie K Scott; Margo M Moore
Journal:  Eukaryot Cell       Date:  2012-08-17

Review 6.  Bacteriophages and phage-inspired nanocarriers for targeted delivery of therapeutic cargos.

Authors:  Mahdi Karimi; Hamed Mirshekari; Seyed Masoud Moosavi Basri; Sajad Bahrami; Mohsen Moghoofei; Michael R Hamblin
Journal:  Adv Drug Deliv Rev       Date:  2016-03-17       Impact factor: 15.470

Review 7.  Phage display creates innovative applications to combat hepatitis B virus.

Authors:  Wen Siang Tan; Kok Lian Ho
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

8.  CD4+ T cells provide intermolecular help to generate robust antibody responses in vaccinia virus-vaccinated humans.

Authors:  Liusong Yin; J Mauricio Calvo-Calle; John Cruz; Frances K Newman; Sharon E Frey; Francis A Ennis; Lawrence J Stern
Journal:  J Immunol       Date:  2013-05-10       Impact factor: 5.422

Review 9.  Filamentous bacteriophage fd as an antigen delivery system in vaccination.

Authors:  Antonella Prisco; Piergiuseppe De Berardinis
Journal:  Int J Mol Sci       Date:  2012-04-24       Impact factor: 6.208

10.  In vivo characteristics of targeted drug-carrying filamentous bacteriophage nanomedicines.

Authors:  Lilach Vaks; Itai Benhar
Journal:  J Nanobiotechnology       Date:  2011-12-20       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.